USP1 inhibitor(Satyarx Pharma)

Just months after starting a Phase I/II trial of its solid tumour candidate TNG348, Tango Therapeutics said Thursday that it will discontinue development of the USP1 inhibitor because several participants experienced liver toxicities.The study enrolled patients with BRCA1/2-mutant and other homologous recombination deficient cancers and dosed the first participant with TNG348 in January. According to Tango, grade 3/4 liver function abnormalities were observed in patients who remained on the study for more than eight weeks. “Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced by patients in the trial,” CEO Barbara Weber said in a statement. TNG348 was in-licensed in 2020 from Medivir, who was eligible for development and commercial milestones on the programme, as well as royalties.The company’s portfolio now includes three clinical assets in Phase I/II studies for cancer: TNG908 and TNG462, which both inhibit PRMT5; and TNG260, a highly selective CoREST complex inhibitor.